Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.
Year of Publication
Zangwill, Kenneth M; Treanor, John J; Campbell, James D; Noah, Diana L; Ryea, Jennifer
J Infect Dis
2008 Feb 15
Adult; Female; Humans; Immunization Schedule; Immunization, Secondary; Immunologic Memory; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Vaccines, Inactivated
UNLABELLED: Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18-64 years of age (placebo and 7.5-, 15-, 45-, or 90-microg doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter. Microneutralization (MN) and hemagglutination-inhibition geometric mean titers (GMTs) of antibody declined before the third dose. Twenty-eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90-, 45-, 15-, and 7.5-mug-dose groups had a MN GMT > or =1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (
TRIAL REGISTRATION: Clinical Trials.gov identifier NCT00240968 .).